Kezar Life Sciences (KZR) Competitors $3.97 -0.01 (-0.25%) Closing price 04:00 PM EasternExtended Trading$3.98 +0.00 (+0.13%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KZR vs. TARA, FTLF, ANEB, OKYO, CRDL, CRBP, CNTB, ALTS, TNYA, and ATOSShould you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include Protara Therapeutics (TARA), FitLife Brands (FTLF), Anebulo Pharmaceuticals (ANEB), OKYO Pharma (OKYO), Cardiol Therapeutics (CRDL), Corbus Pharmaceuticals (CRBP), Connect Biopharma (CNTB), ALT5 Sigma (ALTS), Tenaya Therapeutics (TNYA), and Atossa Genetics (ATOS). These companies are all part of the "pharmaceutical products" industry. Kezar Life Sciences vs. Its Competitors Protara Therapeutics FitLife Brands Anebulo Pharmaceuticals OKYO Pharma Cardiol Therapeutics Corbus Pharmaceuticals Connect Biopharma ALT5 Sigma Tenaya Therapeutics Atossa Genetics Protara Therapeutics (NASDAQ:TARA) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment. Does the media prefer TARA or KZR? In the previous week, Protara Therapeutics and Protara Therapeutics both had 8 articles in the media. Protara Therapeutics' average media sentiment score of 0.84 beat Kezar Life Sciences' score of 0.49 indicating that Protara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Kezar Life Sciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is TARA or KZR more profitable? Protara Therapeutics' return on equity of -36.87% beat Kezar Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Protara TherapeuticsN/A -36.87% -33.85% Kezar Life Sciences N/A -59.99%-48.93% Do analysts rate TARA or KZR? Protara Therapeutics presently has a consensus price target of $19.60, suggesting a potential upside of 546.86%. Kezar Life Sciences has a consensus price target of $9.00, suggesting a potential upside of 126.70%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Protara Therapeutics is more favorable than Kezar Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Kezar Life Sciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has higher valuation and earnings, TARA or KZR? Protara Therapeutics has higher earnings, but lower revenue than Kezar Life Sciences. Protara Therapeutics is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtara TherapeuticsN/AN/A-$44.60M-$1.62-1.87Kezar Life Sciences$7M4.15-$83.74M-$10.82-0.37 Do institutionals & insiders have more ownership in TARA or KZR? 38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are held by institutional investors. 8.4% of Protara Therapeutics shares are held by insiders. Comparatively, 10.4% of Kezar Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, TARA or KZR? Protara Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. SummaryProtara Therapeutics beats Kezar Life Sciences on 10 of the 14 factors compared between the two stocks. Get Kezar Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KZR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZR vs. The Competition Export to ExcelMetricKezar Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.02M$3.13B$5.68B$9.81BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-0.4120.7730.6825.56Price / Sales4.15370.75464.10116.64Price / CashN/A43.0338.2159.48Price / Book0.258.608.996.13Net Income-$83.74M-$54.65M$3.25B$264.89M7 Day Performance-1.00%6.55%4.78%2.67%1 Month Performance-14.07%9.54%6.80%3.11%1 Year Performance-36.44%14.08%30.61%25.14% Kezar Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZRKezar Life Sciences3.8436 of 5 stars$3.97-0.3%$9.00+126.7%-34.7%$29.02M$7M-0.4160Earnings ReportShort Interest ↑TARAProtara Therapeutics2.1655 of 5 stars$3.16+3.3%$20.50+548.7%+61.1%$118.06MN/A-1.8430Earnings ReportAnalyst RevisionFTLFFitLife Brands4.1972 of 5 stars$13.05+4.4%$20.50+57.1%+6.3%$117.39M$64.47M15.5420News CoverageEarnings ReportAnalyst ForecastANEBAnebulo Pharmaceuticals2.2451 of 5 stars$2.70-5.3%$5.50+103.7%+26.8%$117.09MN/A-10.384Short Interest ↑Gap UpOKYOOKYO Pharma3.1547 of 5 stars$3.12+0.6%$7.00+124.4%+164.0%$116.59MN/A0.007Gap UpHigh Trading VolumeCRDLCardiol Therapeutics2.5622 of 5 stars$1.28-7.2%$8.00+525.0%-32.7%$114.09MN/A-3.7620News CoveragePositive NewsEarnings ReportHigh Trading VolumeCRBPCorbus Pharmaceuticals4.3065 of 5 stars$9.34+0.3%$49.38+428.6%-81.5%$113.92MN/A-2.2140CNTBConnect Biopharma3.3366 of 5 stars$2.04+2.0%$7.00+243.1%+83.8%$111.12M$26.03M0.00110News CoveragePositive NewsAnalyst ForecastShort Interest ↓Analyst RevisionALTSALT5 Sigma0.6351 of 5 stars$6.81+8.4%N/A+321.6%$109.61M$12.53M0.00170News CoverageOptions VolumeTNYATenaya Therapeutics3.0436 of 5 stars$0.69+3.4%$6.25+801.5%-66.5%$109.08MN/A-0.60110ATOSAtossa Genetics2.8931 of 5 stars$0.83+1.3%$6.17+639.7%-37.1%$106.31MN/A-3.978Earnings ReportAnalyst Revision Related Companies and Tools Related Companies TARA Competitors FTLF Competitors ANEB Competitors OKYO Competitors CRDL Competitors CRBP Competitors CNTB Competitors ALTS Competitors TNYA Competitors ATOS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KZR) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kezar Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access